id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-2796-0003,FDA,FDA-2022-N-2796,Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN (Aspirin) Tablets,Notice,Withdrawal,2023-07-21T04:00:00Z,2023,7,2023-07-21T04:00:00Z,,2023-07-21T13:27:39Z,2023-15454,0,0,0900006485cf8e61
FDA-2022-N-2796-0002,FDA,FDA-2022-N-2796,Response Letter from FDA CDER to Bristol Myers Products Inc.,Other,Response(s),2022-11-29T05:00:00Z,2022,11,2022-11-29T05:00:00Z,,2022-11-29T18:31:49Z,,0,0,0900006485508d73
FDA-2022-N-2796-0001,FDA,FDA-2022-N-2796,"Bristol Myers Products Inc.; Proposal To Withdraw Approval of a New Drug
Application for Bufferin (Aspirin) Tablets; Opportunity for a Hearing",Notice,Withdrawal,2022-11-23T05:00:00Z,2022,11,2022-11-23T05:00:00Z,2023-01-24T04:59:59Z,2023-02-02T19:29:11Z,2022-25516,0,0,09000064854fe483